JNJ’s Stelara Witnessed High Growth in 3Q17



Stelara revenue trends

In 3Q17, Johnson & Johnson’s (JNJ) Stelara generated revenues of $1.1 billion, which reflected ~38% growth on a YoY basis and 14% growth on a quarter-over-quarter basis. In 3Q17, in the US market and international markets, Stelara generated revenues of $800 million and $324 million, respectively, compared to $561 million and $253 million in 3Q16.

Stelara reported YTD (year-to-date) September 2017 revenues of $2.9 billion compared to $2.3 billion in YTD September 2016. Stelara (ustekinumab) is used to treat moderate-to-severe Crohn’s disease, plaque psoriasis, and active psoriatic arthritis.

Recent approval

In October 2017, the U.S. Food and Drug Administration (FDA) approved Stelara for the treatment of individuals aged above 12 years (adolescents) with moderate to severe plaque psoriasis who are subjects for systemic therapy or phototherapy.

The U.S. FDA approval of Stelara is based on the results of the phase three trial that evaluated the safety and efficacy of the subcutaneous administration of Stelara in individuals aged 12 years or above with moderate-to-severe psoriatic arthritis. In the phase three trial, two-thirds of patients on Stelara responded to the week 12 primary endpoint after two doses at week 0 and 4. The safety parameters were consistent with earlier studies that were conducted on adults with plaque psoriasis.

Stelara’s peers in the plaque psoriasis marketplace include Celgene’s (CELG) Otezla, Valeant Pharmaceuticals’ (VRX) Siliq, and Eli Lilly’s (LLY) Taltz. In 3Q17, Otezla, Siliq, and Taltz reported revenues of $308 million and $151 million, respectively.

In 3Q17, Johnson & Johnson generated revenues of $3.2 billion from its immunology portfolio, which reflected ~6% growth on a YoY basis and 10% growth quarter-over-quarter.

The growth in sales of Johnson & Johnson’s immunology portfolio could boost the share prices of the Vanguard Dividend Appreciation ETF (VIG). Johnson & Johnson makes up about ~4.1% of VIG’s total portfolio holdings.

More From Market Realist